This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Weight gain, raised BP risk seen for HIV patients switching to dolutegravir

Weight gain, raised BP risk seen for HIV patients switching to dolutegravir

For Black patients with HIV on antiretroviral therapy (ART), those who switch from efavirenz to dolutegravir gain more weight and have an increased risk for hypertension, according to a study published in the March issue of eClinicalMedicine.

Alana T. Brennan, Ph.D., M.P.H., from Boston University School of Public Health, and colleagues conducted a involving adults of Black African ancestry with HIV who initiated ART between January 2010 and December 2020. The effect of switching from efavirenz to dolutegravir was examined on weight change and hypertension 12 months after exposure. Unexposed patients remaining on efavirenz were propensity score-matched in a 1:1 ratio with exposed patients who switched from efavirenz to dolutegravir (794 and 794 patients, respectively).

The researchers found that from start of follow-up to 12 months, exposed patients had a higher mean change in weight than unexposed patients (1.78 kg). In addition, those exposed to dolutegravir had a 14.2 percent increase in the risk for hypertension compared with those who were unexposed and remained on efavirenz.

"The gain in weight was expected—this has been described in many other studies, and appears to be a mitigating effect of efavirenz in a substantial number of patients, rather than dolutegravir causing weight gain," Brennan said in a statement. "The blood pressure rise data is less clear, and in some ways more worrying if linked to the drug, as it appears fairly quickly after exposure."

Several authors disclosed financial ties to , including ViiV Healthcare, the manufacturer of dolutegravir.

More information: Alana T. Brennan et al, Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa, eClinicalMedicine (2023). DOI: 10.1016/j.eclinm.2023.101836

Journal information: EClinicalMedicine

Copyright © 2023 HealthDay. All rights reserved.

Citation: Weight gain, raised BP risk seen for HIV patients switching to dolutegravir (2023, March 21) retrieved 12 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

HIV drug may be linked to increased risk of hypertension


Feedback to editors